{"id":"NCT00125190","sponsor":"Ipsen","briefTitle":"Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency","officialTitle":"Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With Primary IGF-1 Deficiency: A Multi-Center, Open Label, Concentration-Controlled Study","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2005-07","primaryCompletion":"2009-01","completion":"2009-01","firstPosted":"2005-07-29","resultsPosted":"2010-04-15","lastUpdate":"2020-07-27"},"enrollment":45,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Insulin-Like Growth Factor-1 Deficiency","Growth Disorders"],"interventions":[{"type":"DRUG","name":"rhIGF-1 (mecasermin) for a period of 86 weeks","otherNames":[]}],"arms":[{"label":"rhIGF-1 QD","type":"EXPERIMENTAL"}],"summary":"This study is intended to assess the effects of once daily dosing of recombinant human insulin-like growth factor (rhIGF-1) in increasing height velocity.","primaryOutcome":{"measure":"Height Velocity From Pretreatment (Week 0) to Week 34","timeFrame":"Pretreatment to Week 34","effectByArm":[{"arm":"rhIGF-1 QD","deltaMin":7,"sd":1.5}],"pValues":[]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":45},"commonTop":["Vomiting","Headache","Pyrexia","Upper Respiratory Tract Infection","Cough"]}}